GlassScriptPhysician profile
Elena B Stybel
NPI 1477638179
$29,251.00
in general payments reported to CMS, 2019-2025
64 companies · $4,455 in 2025
The $4,455 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,112 · 2020: $2,720 · 2021: $4,863 · 2022: $4,486 · 2023: $4,879 · 2024: $4,735 · 2025: $4,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,069.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,401.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,982.61 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,596.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,731.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $1,297.19 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $1,258.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,185.42 | 2021-2025 | |
| Amgen INC. | $1,057.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $1,038.15 | 2023-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $1,008.71 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $906.06 | 2019-2025 | |
| Pfizer INC. | $690.80 | 2019-2025 | |
| Horizon Therapeutics Plc | $509.92 | 2019-2023 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.56 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.13 | 2019-2024 | Ofev |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.68 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $351.50 | 2021-2023 | Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $339.44 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $337.16 | 2024-2025 | Zenpep |
| Shield Therapeutics INC | $304.78 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $269.49 | 2022 | |
| Allergan, INC. | $248.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $245.68 | 2023-2025 | Austedo Xr, Austedo |
| Sumitomo Pharma America, INC. | $244.56 | 2024-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $240.98 | 2024-2025 | Auvelity, Symbravo |
| Alkermes, INC. | $234.94 | 2023-2024 | Lybalvi |
| Kowa Pharmaceuticals America, INC. | $207.58 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Merck Sharp & Dohme LLC | $155.65 | 2019-2021 | |
| Neurelis, INC. | $150.00 | 2024 | Valtoco |
| Sk Life Science, INC. | $144.22 | 2022 | |
| Intra-Sana Laboratories | $143.17 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Daiichi Sankyo INC. | $139.21 | 2021-2023 | Injectafer |
| Idorsia Pharmaceuticals US INC | $124.99 | 2022 | |
| Endo Pharmaceuticals INC. | $109.83 | 2021-2022 | |
| Astellas Pharma US INC | $104.54 | 2020-2025 | Myrbetriq, Veozah |
| Impel Pharmaceuticals INC. | $103.52 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $100.00 | 2024 | Gvoke Hypopen |
| Vivus LLC | $86.86 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $85.12 | 2023-2025 | Ztlido |
| Ironwood Pharmaceuticals, INC | $78.37 | 2021-2023 | Linzess |
| Ardelyx, INC. | $66.66 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $65.70 | 2019-2021 | |
| Genentech USA, INC. | $51.08 | 2019-2020 | |
| Renalytix Ai, INC. | $46.00 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $44.44 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $38.48 | 2021 | |
| Amneal Pharmaceuticals LLC | $35.84 | 2021-2022 | |
| Intuity Medical INC | $32.47 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Acerus Pharmaceuticals Corporation | $31.06 | 2022 | |
| Bardy Diagnostics, INC. | $30.69 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $30.37 | 2021 | |
| Boston Scientific Corporation | $28.59 | 2021 | |
| Medtronic, INC. | $24.65 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.24 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.74 | 2019 | |
| Abbott Laboratories | $22.51 | 2022 | |
| Lundbeck LLC | $21.93 | 2024 | Rexulti |
| Corcept Therapeutics | $20.84 | 2025 | Korlym |
| Indivior INC. | $20.00 | 2021 | |
| Eisai INC. | $18.16 | 2025 | |
| Gilead Sciences, INC. | $15.06 | 2022 | |
| Circassia INC. | $14.29 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.73 | 2019 | |
| Redhill Biopharma INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Stybel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.